摘要:
Disclosed are: aqueous parenteral formulations for the treatment of cancer tumors comprising 1,2,4-benzotriazine 1,4-dioxides in a citrate buffer; and method of cancer tumor treatment.
摘要:
The invention relates to a 2-(diaza-bicyclo-alkyl)-pyrimidone derivative represented by formula (I) or a salt thereof: wherein:
R1 represents a hydrogen atom, a C 1-6 alkyl group or a halogen atom; R2 represents a hydrogen atom, a C 1-6 alkyl group optionally substituted by 1 to 4 substituents selected from a halogen atom, a hydroxyl group or a C 1-4 alkoxy group; a C 1-2 perhalogenated alkyl group, a benzyl group, a phenethyl group, a benzyloxycarbonyl group, a C 1-4 alkoxy carbonyl group, a benzene ring, a naphthalene ring, a quinoline ring, a phthalazine ring, a 5,6,7,8-tetrahydronaphthalene ring, a pyridine ring, an indole ring, a pyrrole ring, a thiophene ring, a benzenesulfonyl group, a benzoyl group, a pyridazine ring, a furan ring or an imidazole ring; the benzyl group, the phenethyl group, the benzyloxycarbonyl group, the benzenesulfonyl group, the benzoyl group and the rings being optionally substituted by 1 to 4 substituents selected from a C 1-6 alkyl group, a benzene ring, a halogen atom, a C 1-2 perhalogenated alkyl group, a C 1-3 halogenated alkyl group, a hydroxyl group, a C 1-4 alkoxy group, a nitro, a cyano, an amino, a C 1-6 monoalkylamino group or a C 2-10 dialkylamino group; R3 represents a 2, 4 or 5-pyrimidine ring optionally substituted by a C 1-4 alkyl group, C 1-4 alkoxy group or a halogen atom; R4 represents a C 1-4 alkyl group optionally substituted by a hydroxyl group, a C 1-4 alkoxy group or a halogen atom and n represents 1 or 2.
The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β, such as Alzheimer disease.
摘要:
The invention concerns irbesartan form A having a modified crystalline habit such that length/width ratio ranges between 1:1 and 10:1, preferably between 1:1 and 5:1 and a method for preparing said crystalline habit. The method is characterised in that it consists in either subjecting a crystalline suspension of irbesartan form A having acicular habit to at least a temperature oscillating step, or in subjecting a crystalline suspension of irbesartan form A having acicular habit to a mechanical shearing. The invention also concerns a pharmaceutical composition containing said irbesartan crystalline habit.
摘要:
The invention concerns compounds of formula (I) wherein: X represents N or CH; R1 represents a hydrogen or halogen atom, or a CF3 group; R2 and R3 independently represent a hydrogen atom or a methyl group; n is 0 or 1; A represents a group of formula (a) or (b) wherein: R4 represents a hydrogen or halogen atom, a C1-C4 alkyl group, a CF3 group, an amino, mono(C1-C4)alkylamino, di(C1-C4)alkylamino; R5 represents a hydrogen or halogen atom, a (C1-C4)alkoxy group, a (C1-C4)alkyl group or a CF3 group; R6 represents a hydrogen atom, a (C1-C4)alkyl group or a (C1-C4)alkoxy group; and their salts or solvates, pharmaceutical compositions containing them, a method for preparing them and the synthesis intermediates in said method.
摘要:
The invention concerns phenoxypropanolamines of formula (I) wherein: R1 represents a hydrogen, a -S(O)z-(C1-C4)Alk-R' group, R' being H, phenyl or (C1-C4) alkoxy), -NHSO2-(C1-C4) Alk, NHCO(C1-C4) Alk; m and n are each independently 0, 1 or 2; R2 and R3 represent independently a hydrogen, a (C5-C6) alkyl, (C3-C6) cycloalkyl, (C1-C4) alkoxy, hydroxy(C1-C4)alkyl, (C1-C4) alkoxy-(C1-C4)alkyl, mono-or di-(C1-C4)Alk-amino(C1-C4)alkyl, pyrrolidino-(C1-C4)alkyl, phenylamino, (C2-C4)alkenyl group, or an aromatic or heteroaromatic group substituted or not with a group R4; R2 and R3 can also together constitute a saturated or unsaturated cycle of 3 to 6 atoms capable of bearing a (C1-C4) alkyl, amino(C1-C4)alkyl, carbamoyl or benzyl substituent; R4 represents a hydrogen or a halogen, a -CO(C1-C4)Alk group or a -NHSO2-(C1-C4)Alk group; a (C1-C4)Alk group, a (C1-C4)alkoxy group, a halogen, -COOH, -COO(C1-C4)Alk, -CN, -CONR3R4, -NO2, -SO2NH2, -NHSO2(C1-C4)Alk; z is 1 or 2; and their salts and solvates. Said compounds have an agonist activity with respect to β-3 adrenergic receptors.
摘要:
A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof having inhibitory activity against tau protein kinase 1:wherein R1 represents a C¿1?-C12 alkyl group which may be substituted; R represents, for example, a group represented by the following formula (II):wherein R?2 and R3¿ independently represent a hydrogen atom or a C¿1?-C8 alkyl group; R?4¿ represents a benzene ring which may be substituted, a naphthalene ring which may be substituted, an indan ring which may be substituted, a tetrahydronaphthalene ring which may be substituted, or an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom, and having 5 to 10 ring-constituting atoms in total.
摘要:
The invention concerns compounds of formula (I), as well as their addition salts with acids or organic salts, their solvates and/or hydrate(s), exhibiting affinity and selectivity for arginine-vasopressin V1b receptors and/or for ocytocin receptors, and further, for certain compounds an affinity for V1a receptors. The invention also concerns the method for preparing them, intermediate compounds of formula (IV) useful for their preparation, pharmaceutical compositions containing them and their use for preparing medicines.
摘要:
The use of compounds capable of displacing tritiated cis N-cyclohexyl N-ethyl-[3-(3-chloro-4-cyclohexylphenyl)allyl]amine from the receptors thereof, for preparing pharmaceutical compositions useful for preventing cell proliferation, is disclosed.
摘要:
The invention concerns a device for spraying or dispensing a fluid or powdery product on a surface to be treated and/or an intake element (50), comprising: a dispensing member (1), including a dispensing opening (31), said dispensing member being associated with a reservoir (2 ) containing said product and being movable between an inoperative position and a dispensing position; and actuating means for moving said dispensing member (1) towards its dispensing position for delivering a dose of product: The invention is characterised in that the device further comprises: means for measuring distance (20) movable between an inoperative position and their useful position, and arranged in their useful position such that each time the device is used the dispensing opening (31) is located at a fixed predetermined distance from the surface to be treated and/or the intake element (50), the movement of said means for distance measuring (20) from their useful position towards their inoperative position bringing the said dispensing member (1) back towards its inoperative position.